Atlas Trials

Allarity Therapeutics

8 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Allarity Therapeutics

RecordFirmDate
Study of PARPi 2X-121 as Monotherapy and in Combination With Dovitinib in Patients With Advanced Solid Tumors (NCT05571969)Allarity Therapeutics2023-03-08
Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP. (NCT04796324)Allarity Therapeutics2021-03-01
Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer (NCT03878849)Allarity Therapeutics2019-04-15
Clinical Pre-screening Protocol for Ovarian Cancer (NCT03877796)Allarity Therapeutics2019-04-11
Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®) (NCT03643107)Allarity Therapeutics2018-10-17
Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP (NCT03562832)Allarity Therapeutics2018-06-20
Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selected by DRP (NCT03196947)Allarity Therapeutics2017-06-13
Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours (NCT01861496)Allarity Therapeutics2013-04-01

Track Allarity Therapeutics automatically

Every clearance here is in the API, with alerts when new ones post.